CTLA4 and melanoma: Since immune checkpoint blockade targeting PD-1, PD-L1 and CTLA4 has shown promising anti-tumor effects by reversing the immunosuppressive effects of tumors, the expression of immune checkpoints has attracted widespread attention as a biomarker for identifying melanoma patients undergoing immunotherapy34–36.